Ginsenosides Rc, as a novel SIRT6 activator, protects mice against high fat diet induced NAFLD

• Published in: Journal of ginseng research Vol. 47; no. 3; pp. 376 - 384
• Main Authors: Yang, Zehong, Yu, Yuanyuan, Sun, Nannan, Zhou, Limian, Zhang, Dong, Chen, HaiXin, Miao, Wei, Gao, Weihang, Zhang, Canyang, Liu, Changhui, Yang, Xiaoying, Wu, Xiaojie, Gao, Yong
• Format: Journal Article
• Language: English
• Published: Korea (South) Elsevier B.V 01-05-2023; 고려인삼학회; Elsevier
• Subjects: Ginsenosides Rc; NAFLD; PPAR-α; SIRT6; 기타의약학; NAFLD; SIRT6; Ginsenosides Rc; PPAR-α
• ISSN: 1226-8453; 2093-4947
• DOI: 10.1016/j.jgr.2020.07.005

Hepatic lipid disorder impaired mitochondrial homeostasis and intracellular redox balance, triggering development of non-alcohol fatty liver disease (NAFLD), while effective therapeutic approach remains inadequate. Ginsenosides Rc has been reported to maintain glucose balance in adipose tissue, while its role in regulating lipid metabolism remain vacant. Thus, we investigated the function and mechanism of ginsenosides Rc in defending high fat diet (HFD)-induced NAFLD.
Mice primary hepatocytes (MPHs) challenged with oleic acid & palmitic acid were used to test the effects of ginsenosides Rc on intracellular lipid metabolism. RNAseq and molecular docking study were performed to explore potential targets of ginsenosides Rc in defending lipid deposition. Wild type and liver specific sirtuin 6 (SIRT6, 50721) deficient mice on HFD for 12 weeks were subjected to different dose of ginsenosides Rc to determine the function and detailed mechanism in vivo.
We identified ginsenosides Rc as a novel SIRT6 activator via increasing its expression and deacetylase activity. Ginsenosides Rc defends OA&PA-induced lipid deposition in MPHs and protects mice against HFD-induced metabolic disorder in dosage dependent manner. Ginsenosides Rc (20mg/kg) injection improved glucose intolerance, insulin resistance, oxidative stress and inflammation response in HFD mice. Ginsenosides Rc treatment accelerates peroxisome proliferator activated receptor alpha (PPAR-α, 19013)-mediated fatty acid oxidation in vivo and in vitro. Hepatic specific SIRT6 deletion abolished ginsenoside Rc-derived protective effects against HFD-induced NAFLD.
Ginsenosides Rc protects mice against HFD-induced hepatosteatosis by improving PPAR-α-mediated fatty acid oxidation and antioxidant capacity in a SIRT6 dependent manner, and providing a promising strategy for NAFLD.